688331 荣昌生物
已收盘 02-02 15:00:00
资讯
新帖
简况
港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善
智通财经 · 09:25
港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 08:04
医保数据发布再升级；多家药企发布业绩预告
每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿
证券之星 · 02-01 01:32
每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿
荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元
南方财经网 · 01-30
荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元
3万亿赛道的估值锚点，彻底变了
虎嗅APP · 01-26
3万亿赛道的估值锚点，彻底变了
每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股
证券之星 · 01-25
每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股
瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”
智通财经 · 01-23
瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”
港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展
智通财经 · 01-23
港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展
港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%
老虎资讯综合 · 01-23
港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%
荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%
证券之星 · 01-21
荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%
荣昌生物：首次回购19.4144万股
南方财经网 · 01-20
荣昌生物：首次回购19.4144万股
【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加
金吾财讯 · 01-19
【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加
每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议
证券之星 · 01-18
每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
每日经济新闻 · 01-16
荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售
荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可
金吾财讯 · 01-16
荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可
智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元
智通财经 · 01-16
智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元
荣昌生物：调整回购股份价格上限至116元/股
每日经济新闻 · 01-15
荣昌生物：调整回购股份价格上限至116元/股
华西证券：维持荣昌生物(09995)“增持”评级 RC148双抗56亿美元出海
智通财经 · 01-15
华西证券：维持荣昌生物(09995)“增持”评级 RC148双抗56亿美元出海
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好泰它西普和维迪西妥在海外注册研究上的进展
金吾财讯 · 01-14
【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好泰它西普和维迪西妥在海外注册研究上的进展
智通港股通活跃成交|1月13日
智通财经 · 01-13
智通港股通活跃成交|1月13日
加载更多
公司概况
公司名称：
荣昌生物制药(烟台)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-31
主营业务：
荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。
发行价格：
48.00
{"stockData":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":98.5,"timestamp":1770015600000,"preClose":102.25,"halted":0,"volume":8201279,"delay":0,"changeRate":-0.0367,"floatShares":163000000,"shares":564000000,"eps":-1.6788,"marketStatus":"已收盘","change":-3.75,"latestTime":"02-02 15:00:00","open":102.25,"high":104.64,"low":97.81,"amount":828000000,"amplitude":0.0668,"askPrice":98.58,"askSize":20,"bidPrice":98.5,"bidSize":149,"shortable":0,"etf":0,"ttmEps":-1.6788,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770082200000},"marketStatusCode":5,"adr":0,"adjPreClose":102.25,"symbolType":"stock_kcb","openAndCloseTimeList":[[1769995800000,1770003000000],[1770008400000,1770015600000]],"highLimit":112.48,"lowLimit":92.03,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":564477483,"isCdr":false,"pbRate":23.97,"roa":"--","roe":"--","epsLYR":-2.73,"committee":0.620438,"marketValue":55601000000,"turnoverRate":0.0503,"status":1,"afterMarket":{"amount":0,"volume":0,"close":98.5,"buyVolume":0,"sellVolume":200,"time":1770017637558,"indexStatus":"已收盘 02-02 15:30:00","preClose":102.25},"hkstockBrief":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":80.35,"timestamp":1770019686007,"preClose":84.2,"halted":0,"volume":5264837,"delay":0,"premium":"-27.50"},"floatMarketCap":16065000000},"requestUrl":"/m/hq/s/688331","defaultTab":"news","newsList":[{"id":"2608384558","title":"港股异动 | 荣昌生物(09995)盈喜后涨近4% 预计25年度归母净利润约7.16亿元 公司盈利效率大幅改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2608384558","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608384558?lang=zh_cn&edition=full","pubTime":"2026-02-02 09:25","pubTimestamp":1769995522,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物盈喜后涨近4%，截至发稿，涨3.68%，报87.3港元，成交606.74万港元。消息面上，1月30日，荣昌生物发布公告，经公司财务部门初步测算，预计2025年度营业收入约人民币32.5亿元，与上年同期相比，将增加收入约人民币15.33亿元，同比增加约89%。公司预计2025年度实现归属于母公司所有者的净利润约人民币7.16亿元，与上年同期相比，实现扭亏为盈。综合多方面积极因素，公司盈利效率大幅改善，预计2025年度净利润将实现扭亏为盈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400370.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688331","VT","09995"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU1328615791.USD","LU2580892789.USD","BK0077","BK0046","BK0057","BK0239","LU2488822045.USD","09995","LU2148510915.USD","LU2580892862.HKD","300122","BK0075","BK1161","BK1574","BK4017","688331","LU2328871848.SGD","LU1223082519.USD","BK0028","LU1969619763.USD","LU1064130708.USD","000661","688506","BK0188","BK0196","LU1223082196.USD","LU1064131003.USD","LU1223083913.SGD","CDE"],"gpt_icon":0},{"id":"2608072430","title":"每周股票复盘：荣昌生物（688331）预计2025年净利7.16亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072430","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072430?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:32","pubTimestamp":1769880732,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，荣昌生物报收于102.25元，较上周的102.27元下跌0.02%。本周，荣昌生物1月30日盘中最高价报107.5元。业绩披露要点荣昌生物发布业绩预告，预计2025年全年归属净利润盈利约7.16亿元。公司公告汇总荣昌生物预计2025年度营业收入约325,000万元，同比增长约89%；归属于母公司所有者的净利润约71,600万元，实现扭亏为盈；扣除非经常性损益后的净利润约7,850万元，亦实现扭亏为盈。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000240.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2328871848.SGD","BK1583","LU1064131003.USD","BK1161","LU2148510915.USD","LU1064130708.USD","BK0239","09995","LU1969619763.USD","LU2488822045.USD","688331","BK1574"],"gpt_icon":0},{"id":"2607401314","title":"荣昌生物：2025年全年预计净利润7.16亿元—7.16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607401314","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607401314?lang=zh_cn&edition=full","pubTime":"2026-01-30 17:25","pubTimestamp":1769765136,"startTime":"0","endTime":"0","summary":"南财智讯1月30日电，荣昌生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润约为71,600万元，实现扭亏为盈；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润约为7,850万元，实现扭亏为盈。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303637048943.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688331","09995"],"gpt_icon":0},{"id":"2606122293","title":"3万亿赛道的估值锚点，彻底变了","url":"https://stock-news.laohu8.com/highlight/detail?id=2606122293","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606122293?lang=zh_cn&edition=full","pubTime":"2026-01-26 08:12","pubTimestamp":1769386320,"startTime":"0","endTime":"0","summary":"多只创新药ETF的年内最高涨幅突破50%，多家创新药企股价翻番。不过，我们发现经过验证的靶点，不同企业的BD交易授权下，资本市场也给出了不同反应。且2024年，美国FDA批准了同类首款药物Ensifentrine，为该靶点的成药性提供了关键验证。只不过与海思科不同，恒瑞医药在与GSK的交易公告后，其A股和H股股价均出现了显著上涨。据悉，恒瑞医药获得的5亿美元为纯现金首付款，可以立即确认业绩，展现了GSK对其资产价值的强烈认可和信心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656147805&idx=1&sn=bc6bcda7f82ce0193ae3a090ba46cdc8&chksm=67838d5482c3a023e3be79b5567544c3a508a60a147222d217af39c881d77ba875ce4eab9a04&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["LU1064131003.USD","LU1064130708.USD","AA","LU2488822045.USD","LU2328871848.SGD","GSK.UK","BK4007","BK0239","BK4585","LU1969619763.USD","688331","BK1574","09995","06978","GSK","LU2148510915.USD","LU1829250122.USD","BK1583","BK4588","BK4532","BK4153","BK1161"],"gpt_icon":0},{"id":"2606234089","title":"每周股票复盘：荣昌生物（688331）首次回购股份19.4144万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606234089","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606234089?lang=zh_cn&edition=full","pubTime":"2026-01-25 02:04","pubTimestamp":1769277852,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，荣昌生物报收于102.27元，较上周的107.25元下跌4.64%。本周，荣昌生物1月19日盘中最高价报109.38元。本周关注点公司公告汇总：荣昌生物首次回购股份19.4144万股，支付资金总额2000.40万元。荣昌生物制药（烟台）股份有限公司完成2022年及2023年A股限制性股票激励计划相关权益归属，共计归属767,240股，涉及激励对象142人。股本总数由563,710,243股增至564,477,483股，实际控制人未发生变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500000541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331","BK1583","BK0239","LU2148510915.USD","LU2328871848.SGD","BK1574","LU1064130708.USD","BK1161","LU1969619763.USD","LU2488822045.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2605262484","title":"瑞银：将荣昌生物目标价一举升至120港元 评级上调至“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2605262484","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605262484?lang=zh_cn&edition=full","pubTime":"2026-01-23 13:58","pubTimestamp":1769147880,"startTime":"0","endTime":"0","summary":"瑞银发布研报称，将荣昌生物(09995)的评级由“中性”上调至“买入”，目标价由63.8港元一举升至120港元。瑞银对荣昌生物与艾伯维集团(AbbVie)的合作持积极看法，该合作授予RC148(PD-1/VEGF) ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260123/c674256316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688331"],"gpt_icon":0},{"id":"2605744726","title":"港股异动 | 荣昌生物(09995)涨近4% 机构指公司与艾伯维合作有望促进RC148研发与全球商业化拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2605744726","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605744726?lang=zh_cn&edition=full","pubTime":"2026-01-23 10:41","pubTimestamp":1769136116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物涨近4%，截至发稿，涨2.96%，报92.3港元，成交2.06亿港元。该行认为，艾伯维作为一间跨国制药公司，应能促进RC148在研发和商业化方面的全球扩展，并对RC148的差异化发展策略持正面态度。该行相信，首付款支付将扭转荣昌生物的净负债状况，并预计未来多项新药获批将使公司自2026年起持续达到盈亏平衡。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1610","BK1161","LU1969619763.USD","LU2328871848.SGD","BK1583","LU2488822045.USD","LU1064130708.USD","LU2148510915.USD","688331","LU1064131003.USD","BK0239","09995","BK1574"],"gpt_icon":0},{"id":"1199361007","title":"港股生物医药股普涨！康方生物涨超5%，荣昌生物涨超3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199361007","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199361007?lang=zh_cn&edition=full","pubTime":"2026-01-23 09:54","pubTimestamp":1769133269,"startTime":"0","endTime":"0","summary":"1月23日，港股生物医药股普涨，$康方生物(09926)$涨超5%，$荣昌生物(09995)$涨超3%，$泰格医药(03347)$、$君实生物(01877)$、$百济神州(06160)$、$药明合联(02268)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"de741e781d04bd03f8ca00d2fa57ffc6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","IE00BPRC5H50.USD","LU0417516902.SGD","LU1794554557.SGD","LU0348827113.USD","BK1161","BK4588","LU0348784397.USD","LU0417516571.SGD","LU0634319403.HKD","688331","LU0348767384.USD","LU2399975544.HKD","LU0348735423.USD","LU2476274308.USD","09926","LU2148510915.USD","LU1064130708.USD","LU0348783233.USD","LU0348766576.USD","LU2488822045.USD","LU2476274720.SGD","BK0239","LU0561508036.HKD","BK1574","399441","IE00B5MMRT66.SGD","BK1610","02800","BK4585","LU0417516738.SGD","LU0540923850.HKD","LU1961090484.USD","LU2328871848.SGD","09995","LU1969619763.USD","161726","LU2778985437.USD","IE00B543WZ88.USD","LU1064131003.USD","LU1720050803.USD","LU0348825331.USD","BK1583"],"gpt_icon":0},{"id":"2605488754","title":"荣昌生物（688331）披露限制性股票激励计划归属结果，1月21日股价下跌0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605488754","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605488754?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:17","pubTimestamp":1769005037,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，荣昌生物报收于103.53元，较前一交易日下跌0.07%，最新总市值为584.4亿元。公司近日发布公告称，荣昌生物制药（烟台）股份有限公司已完成2022年及2023年A股限制性股票激励计划相关权益的归属，共计归属767,240股，涉及激励对象142人。本次归属新增股份已于2026年1月20日完成登记，上市流通日期为2026年1月26日。股本总数由563,710,243股增至564,477,483股，实际控制人未发生变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100040789.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","09995","LU2148510915.USD","LU2488822045.USD","BK1574","BK0239","BK1583","LU1064130708.USD","LU1969619763.USD","LU2328871848.SGD","LU1064131003.USD","688331"],"gpt_icon":0},{"id":"2604923661","title":"荣昌生物：首次回购19.4144万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923661","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923661?lang=zh_cn&edition=full","pubTime":"2026-01-20 18:53","pubTimestamp":1768906388,"startTime":"0","endTime":"0","summary":"南财智讯1月20日电，荣昌生物公告，公司于2026年1月20日通过上海证券交易所交易系统以集中竞价交易方式首次回购股份194,144股，占公司总股本的0.0344%，回购价格区间为102.17元/股至103.78元/股，支付资金总额为2000.40万元（不含交易费用）。本次回购方案已实施完成，实际回购金额为2000.40万元，在预计回购金额2000万元至4000万元范围内。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601203624836419.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","688331","LU2328871848.SGD","BK1583","LU1969619763.USD","BK1574","LU2148510915.USD","09995","LU2488822045.USD","BK0239","LU1064130708.USD","LU1064131003.USD"],"gpt_icon":0},{"id":"2604864900","title":"【券商聚焦】中泰国际上调荣昌生物(09995)评级至“买入” 指泰它西普与维迪西妥单抗的2025年销售收入将快速增加","url":"https://stock-news.laohu8.com/highlight/detail?id=2604864900","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604864900?lang=zh_cn&edition=full","pubTime":"2026-01-19 13:47","pubTimestamp":1768801676,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中泰国际研报指，荣昌生物 日前与全球行业巨头艾伯维签订关于肿瘤领域的双抗药物RC148的授权协议，公司将授予艾伯维RC148在大中华区以外地区的的开发、生产和商业化的独家权利，协议获准后公司将获6.5亿美元的首付款及最高49.5亿美元的开发、监管和商业化里程碑付款，以及在大中华以外地区净销售额的两位数分级特许权使用费。艾伯维的认可表明产品临床数据优异，而且首付款将显著夯实资金。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973487","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688331","09995"],"gpt_icon":0},{"id":"2604928774","title":"每周股票复盘：荣昌生物（688331）与艾伯维签署49.5亿美元授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2604928774","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604928774?lang=zh_cn&edition=full","pubTime":"2026-01-18 01:59","pubTimestamp":1768672747,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，荣昌生物报收于107.25元，较上周的96.96元上涨10.61%。本周，荣昌生物1月13日盘中最高价报114.46元。本周关注点交易信息汇总：荣昌生物因涨幅达15%登上龙虎榜。公司公告汇总：荣昌生物与艾伯维签署RC148全球授权协议，获6.5亿美元首付款及最高49.5亿美元里程碑付款。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000404.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","LU2488822045.USD","688331","BK0239","LU1969619763.USD","LU2328871848.SGD","BK1583","BK1574","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","09995"],"gpt_icon":0},{"id":"2603967864","title":"荣昌生物：公司尚无药品在欧盟获批上市，无药品向欧盟出口销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2603967864","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603967864?lang=zh_cn&edition=full","pubTime":"2026-01-16 18:25","pubTimestamp":1768559151,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：请问近两年是否出口欧盟国家？荣昌生物（688331.SH）1月16日在投资者互动平台表示，公司尚无药品在欧盟获批上市，无药品向欧盟出口销售，未来业务的开展情况，还请您关注公司的相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601163622035255.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601163622035255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU2488822045.USD","BK1574","BK1583","LU2148510915.USD","09995","BK1161","688331","LU1064130708.USD","BK0239","LU1969619763.USD","LU2328871848.SGD"],"gpt_icon":0},{"id":"2603954004","title":"荣昌生物(09995)升3.45% 与艾伯维就RC148达成独家授权许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2603954004","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603954004?lang=zh_cn&edition=full","pubTime":"2026-01-16 13:35","pubTimestamp":1768541754,"startTime":"0","endTime":"0","summary":"金吾财讯 | 荣昌生物(09995)股价午后维持高位，截至发稿，升3.45%，报97.65港元，成交额3.21亿港元。交银国际研究报告指，荣昌生物与艾伯维就RC148达成独家授权许可协议，后者将获得RC148大中华区以外开发、生产和商业化的独家权利，荣昌生物将收到6.5亿美元首付，并最高49.5亿美元的里程碑收款，以及两位数百分比的分级销售提成。该行上调荣昌生物2026至27年的收入预测，升目标价至136港元。2026年看好泰它西普和维迪西妥在海外注册研究上的进展，以及早期品种在更多适应症上的进展。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241105/OGZjY2Y5NjEzNTIxNjU5NDU5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973389","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131003.USD","BK1574","LU1969619763.USD","LU2328871848.SGD","BK1161","LU2148510915.USD","LU2488822045.USD","09995","688331","LU1064130708.USD","BK1583","BK0239"],"gpt_icon":0},{"id":"2603349619","title":"智通港股早知道 | 央行下调各类结构性货币工具25个基点 国家电网“十五五”计划投资4万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603349619","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603349619?lang=zh_cn&edition=full","pubTime":"2026-01-16 07:52","pubTimestamp":1768521142,"startTime":"0","endTime":"0","summary":"修订后的eCTD相关技术文件由国家药监局药品审评中心另行发布。国家电网“十五五”计划投资4万亿元据中国电力报消息，国家电网“十五五”投资计划出炉：“十五五”期间，国家电网公司固定资产投资预计达到4万亿元，较“十四五”投资增长40%;将重点聚焦于绿色转型、构建新型电力系统、强化科技赋能等方面。持有屈臣氏集团25%股份的淡马锡寻求在其IPO中退出投资。双方所持股份均设有5年锁定期。2025年公司获得钠电千吨级订单并出货。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"66a50ec980ff2cb7251ac80144af961f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02190","LU0149721374.USD","LU2213484517.USD","BK1100","BK4526","BK4531","02465","BK1116","BK1569","BK1583","LU1880383366.USD","BK4581","BK1574","ZBmain","BK1151","02579","BK4509","09995","BK4532","ZFmain","BK1587","BK4099","ZTmain","LU1571399168.USD","002352","BK4548","09866","TNmain","603906","BK1592","LU0072462343.USD","BK1500","LU0164880469.USD","LU0320764599.SGD","ZNmain","BK4574","603993","NIO.SI","BK4534","NIO","IE0032431581.USD","BK1230","LU1969619763.USD","300919","BK1594","EVS.SI","BK4505","LU1481107354.HKD","BK4585","LU2328871848.SGD","UBmain","06936","BK1521","CKHUY","LU0708995583.HKD","LU1048588211.SGD","BK4555","BK1110","BK4588","688331","LU0052750758.USD","BK4504","BK1161","03993","00001","BK1190","BK1601","LU1880383440.USD"],"gpt_icon":1},{"id":"2603670626","title":"荣昌生物：调整回购股份价格上限至116元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603670626","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603670626?lang=zh_cn&edition=full","pubTime":"2026-01-15 16:55","pubTimestamp":1768467316,"startTime":"0","endTime":"0","summary":"【荣昌生物：调整回购股份价格上限至116元/股】1月15日，荣昌生物公告称，公司拟将回购价格上限由95元/股调整为116元/股，以保障回购股份方案顺利实施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601153620451798.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601153620451798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU1064130708.USD","LU2488822045.USD","LU2328871848.SGD","LU2148510915.USD","BK1574","BK0239","BK1583","LU1969619763.USD","09995","688331","BK1161"],"gpt_icon":0},{"id":"2603027626","title":"华西证券：维持荣昌生物(09995)“增持”评级 RC148双抗56亿美元出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2603027626","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603027626?lang=zh_cn&edition=full","pubTime":"2026-01-15 09:11","pubTimestamp":1768439514,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华西证券发布研报称，维持荣昌生物“增持”评级，公司自主研发实力强劲，核心产品销售稳定增长，管理团队经验丰富，临床适应症管线稳定推进，海内外布局合理，看好公产品上市后商业化运营能力。根据协议，艾伯维将获得RC148在大中华区以外地区的独家开发、生产和商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393091.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","002926","688331"],"gpt_icon":0},{"id":"2603540866","title":"【券商聚焦】交银国际维持荣昌生物(09995)买入评级 看好泰它西普和维迪西妥在海外注册研究上的进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2603540866","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603540866?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:04","pubTimestamp":1768352684,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，荣昌生物 宣布与艾伯维就RC148达成独家授权许可协议，后者将获得RC148大中华区以外开发、生产和商业化的独家权利，公司将收到6.5亿美元首付款、最高49.5亿美元的里程碑收款、以及两位数百分比的分级销售提成。随着关键产品相继BD出海，2026年该机构看好泰它西普和维迪西妥在海外注册研究上的进展，以及早期品种在更多适应症上的推进，相关数据读出有望持续催化股价。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/YTg5NTFiOTlmZmEyYmE3ODE4NjgwNzc4MTUzMTI=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973172","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"gpt_icon":0},{"id":"2603168844","title":"智通港股通活跃成交|1月13日","url":"https://stock-news.laohu8.com/highlight/detail?id=2603168844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603168844?lang=zh_cn&edition=full","pubTime":"2026-01-13 19:00","pubTimestamp":1768302001,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年1月13日当天，阿里巴巴-W、腾讯控股、小米集团-W位居沪港通（南向）成交额前3位，成交额分别为81.05 亿元、29.45 亿元、28.57 亿元；阿里巴巴-W、腾讯控股、小米集团-W 位居深港通（南向）成交额前3位，成交额分别为58.01 亿元、23.48 亿元、21.05 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0823413660.USD","LU0828237510.HKD","LU1718418525.SGD","LU0456842615.SGD","LU1720051108.HKD","600941","LU0449509016.USD","SG9999014914.USD","BK4533","LU0823397103.USD","01024","LU0417516571.SGD","LU0516423174.USD","LU1810669033.SGD","LU2008162690.USD","BK4581","IE00B5MMRT66.SGD","LU0348783233.USD","LU0188438112.USD","LU1769817179.HKD","LU2498475776.HKD","LU2328871848.SGD","SGXZ99366536.SGD","LU1328615791.USD","LU0633140560.USD","BK1517","LU2152927971.USD","LU0821914370.USD","LU0080751232.USD","BK1205","LU0683595622.HKD","LU0254981946.USD","HK0000306701.USD","LU0414403682.SGD","LU1814569148.SGD","LU0784639295.USD","SG9999018857.SGD","LU1868837722.USD","LU0051755006.USD","LU0630378692.HKD","LU0251144936.SGD","BK1594","LU0047713382.USD","IE00BZ08YS42.EUR","81024","SG9999007991.SGD","LU0348788117.USD","SG9999002562.SGD","LU0456827905.SGD","LU0326950275.SGD","IE00B543WZ88.USD","LU0589944569.HKD","LU0054450605.USD","LU1251922891.USD","LU0607220059.USD","LU0214875030.USD","LU1282649067.USD","LU0348816934.USD","SG9999006514.SGD","LU1548497426.USD","LU0070217475.USD","LU1328277881.USD","IE00BF5LJ272.USD","LU0648948544.HKD","SG9999001903.USD","LU0370786039.SGD","LU1497733631.SGD","LU0516422440.USD","02269","LU0084288322.USD","LU0210526637.USD","LU2039709279.SGD","LU1226288097.SGD","LU2462611646.USD","LU1868837565.USD","LU2097828805.USD","00883","LU0067412154.USD","LU0269904917.USD","LU0871576103.HKD","BK1584","LU0831093199.SGD","LU1201861165.SGD","LU1770034418.SGD","LU0737861772.HKD","BK1516","LU1481107354.HKD","LU0634319403.HKD","LU0384037296.USD","LU1048588211.SGD","LU1808992512.USD","LU0117841782.USD","BK4504","LU1196710351.USD","SG9999000327.SGD","LU2097828714.EUR","LU2087589342.USD","HK0000252152.HKD","SG9999002828.SGD","IE00B8HQ1Z84.USD","02228","LU0762540952.USD","LU0345775950.USD","LU0106252389.USD","LU1785774172.SGD","LU0320764755.SGD","SG9999001846.SGD","BK1615","HK0000306685.HKD","LU0149534421.HKD","LU0531970944.HKD","LU1196710864.SGD","LU1655091459.SGD","LU2045819591.USD","IE00BGV7N243.SGD","BK0214","SG9999004220.SGD","BK1521","LU1224709979.USD","00981","LU0611395673.USD","LU0320764599.SGD","LU1522347837.USD","LU1048596156.SGD","LU1105468828.SGD","LU0499858438.USD","LU0608807433.USD","LU1497734951.SGD","LU0791591158.USD","LU0762542818.HKD","LU0310800965.SGD","LU0898667661.SGD","HK0000352382.USD","LU0449515922.USD","IE00B0JY6N72.USD","LU1226287792.SGD","LU0880133367.SGD","BK1249","LU0642271901.SGD","IE00B067MR52.USD","LU0588546209.SGD","LU1634259557.SGD","LU0651946864.USD","BK1193","LU0106959298.USD","LU0127658192.USD","LU0264606111.USD","LU0441854154.USD","LU0823039010.USD","LU0455707207.USD","LU2293587155.HKD","LU0823413587.USD","LU1235295612.USD","BK4502","LU0211977185.USD","LU0509642566.USD","LU0588545490.SGD","LU0320764243.SGD","LU0633140727.USD","LU0259732245.USD","LU0143863784.USD","LU2488822045.USD","LU0149721374.USD","LU0140636845.USD","LU0828238088.HKD","LU0541501648.USD","SGXZ90724238.SGD","LU1504937902.USD","LU0823040885.USD","BK4585","LU0661504455.SGD","LU1719994722.HKD","LU2237443978.SGD","09995","LU1634259391.SGD","SG9999017495.SGD","LU0210527791.USD","HK0000352291.HKD","LU0072462343.USD","LU1303224171.USD","BK1590","LU1880383366.USD","METmain","SG9999002463.SGD","LU0315179316.USD","00700","02208","LU0052750758.USD","LU0329678170.USD","BK1604","LU0868486357.SGD","LU2237443895.HKD","IE00B3M56506.USD","LU2257852520.SGD","LU0326948709.USD","LU0501845795.SGD","LU0823426480.USD","BK1141","LU2317271919.USD","LU0463099449.HKD","LU2177674079.SGD","LU0516422366.SGD","01810","LU1282649141.HKD","SGXZ31699556.SGD","IE0003795394.USD","SG9999001051.SGD","LU1720051017.SGD","LU0477156797.USD","BK1163","BK4575","BK4535","LU0072913022.USD","BK4538","LU1226288253.USD","BK1618","LU1734074674.USD","BK4524","LU0345769631.USD","SG9999014898.SGD","LU1497733557.USD","LU0235996351.USD","LU0878004406.USD","LU2362540622.SGD","LU1951186391.HKD","LU1366334651.USD","LU0244354667.USD","LU0128522157.USD","LU0823397285.USD","LU2237443622.USD","IE00B031J352.USD","BK4579","LU0348735423.USD","LU0307460666.USD","LU0348766576.USD","LU0762541174.USD","LU0972618739.USD","LU0328353924.USD","LU0650527681.SGD","LU1226288170.HKD","BK4558","LU2148510915.USD","LU0164880469.USD","LU0878005551.USD","LU1831875114.USD","LU0261947096.USD","BK4220","LU0039217434.USD","LU0561508036.HKD","LU1725190679.HKD","BABA","LU0192582467.USD","LU0287142896.SGD","LU0251143458.SGD","LU1064130708.USD","LU1642822792.SGD","BK4531","BK4614","LU0918141887.USD","LU1675838814.USD","BK1607","IE00BZ08YR35.GBP","LU0469268626.HKD","LU0651947912.USD","LU0672654166.SGD","03690","LU0531971595.HKD","LU0823041008.USD","BK1609","LU1974910355.USD","LU0029874905.USD","LU2476274308.USD","LU0516423091.SGD","LU0228659784.USD","BK1608","LU0128522744.USD","LU0196878994.USD","LU0169518387.USD","BK4503","LU0396098781.USD","LU0708995583.HKD","LU2097828557.USD","SGXZ51526630.SGD","LU2247934214.USD","LU0327786744.USD","LU0345769128.USD","BK4607","LU2051468812.USD","SG9999013353.USD","SG9999001093.SGD","BK1161","BK1506","LU1515016050.SGD","LU0315178854.USD","BK1558","LU2357305700.SGD","LU0164872284.USD","LU0819121731.USD","LU0819123356.HKD","LU0231483743.USD","LU1813983027.USD","LU2226246903.HKD","LU0918141705.HKD","LU0329678337.USD","IE0034224299.USD","80883","LU0164865239.USD","LU0348825331.USD","BK4587","BK4534","LU1051769294.HKD","LU2237443549.SGD","LU0106259558.USD","HK0000320223.HKD","LU2449936058.SGD","BK1591","LU0588545904.SGD","89988","LU0228367735.SGD","LU1044874839.SGD","09988","LU0516422952.EUR","LU0502904849.HKD","LU0577902454.USD","LU1051768304.USD","LU0588545730.USD","00941","SG9999001069.SGD","LU0605514214.HKD","BK1617","SG9999003461.SGD","LU1807302812.USD","IE0032834883.USD","LU0261950983.USD","LU0791590937.USD","LU0211331839.USD","688981","IE00BQXX3F31.USD","LU0543330483.HKD","IE0032431581.USD","BK1142","LU1003077747.HKD","IE0009570106.USD","HTCD.SI","IE00BMPRXN33.USD","LU2279701549.SGD","LU1226287529.USD","IE00B8L5B284.USD","LU0797268264.HKD","SG9999001226.SGD","SG9999015945.SGD","BK1610","LU0985320562.USD","LU1960683339.HKD","LU0130103400.USD","BK1531","LU0488056044.USD","SG9999014880.SGD","LU0049853897.USD","LU1720050803.USD","LU1804176565.USD","09926","LU0107464264.USD","IE00B031HY20.USD","LU1568876335.HKD","LU0890818403.SGD","LU2125910500.SGD","SG9999000418.SGD","BK1095","LU0229945570.USD","002202","HK0000914660.USD","IE00B29SXG58.USD","LU1917777945.USD","LU0594300419.USD","LU0314109678.HKD","LU0348805143.USD","LU1064131003.USD","LU0359201612.USD","LU1282651048.USD","BK1523","SG9999015978.USD","BK1501","LU0499858602.USD","LU0417516738.SGD","LU0359202008.SGD","HXXD.SI","BK4122","LU1823568750.SGD","LU0359201885.HKD","LU1316542783.SGD","LU1770036033.HKD","LU0289960550.SGD","LU0130518102.USD","LU0293314216.USD","LU0417516902.SGD","LU2242644610.SGD","SG9999015986.USD","BK4565","LU1629966141.USD","BK1614","LU0577902298.EUR","600938","BK1233","LU0675040207.SGD","LU1993786604.SGD","688331","LU0708995153.HKD","LU2476274720.SGD","BK1152","LU1102505929.USD","LU2362541513.USD","LU0737861699.HKD","LU0163747925.USD","LU0865486749.SGD","LU0011963245.USD","LU1226287875.USD","IE0008368304.USD","HK0000252160.HKD","IE0031814852.USD","IE00BZ08YT58.USD","KSTmain","IE00B0169N27.USD","LU1733274390.USD","BK1588","LU0540923850.HKD","LU0873338254.USD","LU1046422090.SGD","SG9999018865.SGD","BK1574","LU2237443465.HKD","LU0786609619.USD","LU3063872942.SGD","LU1152091168.USD","LU0049112450.USD","LU0572940350.SGD","LU0054237671.USD","LU1439102457.SGD","LU0608807946.USD","GB00BDT5M118.USD","LU0181495838.USD","LU2097828474.EUR","SGXZ49509284.SGD","LU0348814723.USD","LU2125910849.SGD","LU1961090484.USD","LU1188198961.HKD","LU1733274473.HKD","LU0431992006.USD","SG9999001689.USD","SG9999014906.USD","BK4527","SG9999014674.SGD","LU1235294995.USD","LU0593848301.USD","LU1242518857.USD","SG9999000459.SGD","LU1102505762.USD","SG9999006597.SGD","LU2133065610.SGD","IE00BMPRXR70.SGD","IE0003851619.USD","LU0738911758.USD","LU1323998911.USD","LU1439103000.SGD","LU0949170772.SGD","LU1048484197.HKD","LU0553294199.USD","LU2148611432.USD","LU2265009873.SGD","LU0886674414.USD","LU1211504680.USD","LU0648000940.SGD","LU1880398554.USD","LU0700851271.USD","LU1115378108.SGD","LU1044876610.USD","LU0117844026.USD","LU0862451837.USD","LU0143863198.USD","LU0132412106.USD","LU0203345920.USD","LU0456846285.SGD","LU2362541273.HKD","LU1688375341.USD","IE00BQXX3C00.GBP","LU0572944931.SGD","HBBD.SI","LU0052756011.USD","LU0043850808.USD","LU0197773160.USD","BK1586","LU1023057109.AUD","LU0197773673.USD","IE0008368411.USD","LU0096374516.USD","LU0828237940.HKD","LU1044875133.USD","LU0882747503.HKD","LU0048580855.USD","IE0001KFT4U8.USD","LU1046421795.USD","HK0000914686.HKD","BK1526","BK1502","LU0029875118.USD","LU2097828631.EUR","LU2237443382.USD","LU1568876251.USD","LU0831103253.SGD","LU0862451753.SGD","LU1769817096.USD","IE00BQXX3D17.EUR","LU2251237306.USD","LU0348784397.USD","LU0348723411.USD","SGXZ81514606.USD","BK1238","LU0856984785.SGD","LU1224444064.USD","BK4548","BK4543","LU0061477393.USD","LU0577902611.USD","LU0348767384.USD","IE0008369823.USD","LU0048388663.USD","LU1969619763.USD","LU0128525689.USD","LU0173614495.USD","BK1589","LU0577902371.SGD","LU0210533765.USD","LU0048597586.USD","LU0823038988.USD","LU0572939691.SGD","LU2251237488.HKD","LU1196710195.USD","HMTD.SI","HK0000500386.USD","LU0979878070.USD","BK4526","BK1536","LU1981816686.USD","HK0000165453.HKD","LU0348783662.USD","LU1267930227.SGD","IE0008368742.USD","LU1366334578.USD","LU2106854487.HKD","BK4505","SGXZ81163826.USD","LU1868838027.USD","IE00B0169L03.USD","LU1956131251.USD","LU0543330566.HKD","LU1282648689.USD","LU0738912210.USD","LU0203347892.USD","LU0640798160.USD","LU1880383440.USD","LU1242518931.SGD","BK4588","LU1794554557.SGD","HK0000320264.USD","BK1546","LU0823426308.USD","LU1282651121.HKD","LU0345776255.USD","LU2778985437.USD","BK1528","LU0348827113.USD","LU0594300179.USD","LU1880398471.USD","BK4554","LU0545039389.USD","LU2097829019.USD","LU0630378429.USD","IE0003895053.USD","81810","LU0175139822.USD","IE00B031HW06.USD","LU2399975544.HKD","LU1883866441.USD","IE00BPRC5H50.USD","LU0577902538.SGD","LU2023250504.SGD","IE00BFMHRM44.USD","BK1576","BK1583","BK1513","LU1282649810.SGD","LU0541502299.USD","SG9999015952.SGD","BK1575","LU1008478684.HKD","LU0165289439.USD","LU1152091754.HKD","IE00B97KM107.HKD"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770027688812,"stockEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.3144},{"period":"3month","weight":0.0316},{"period":"6month","weight":0.631},{"period":"1year","weight":2.6701},{"period":"ytd","weight":0.3144}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0376},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.1567},{"period":"1year","weight":0.2668},{"period":"ytd","weight":0.0376}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"荣昌生物制药(烟台)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15248人(较上一季度增加18.39%)","perCapita":"10696股","listingDate":"2022-03-31","address":"山东省烟台市福山区中国(山东)自由贸易试验区烟台片区烟台开发区北京中路58号","registeredCapital":"56447万元","survey":" 荣昌生物制药(烟台)股份有限公司的主营业务是抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物的研发、生产和销售。公司的主要产品是泰它西普、维迪西妥单抗、RC28、RC88、RC148、RC278、RC288。泰它西普发明专利先后获得中国、美国、欧洲等国家和地区的授权，得到了国家“十一五”、“十二五”、“十三五”期间“重大新药创制”科技重大专项支持。","listedPrice":48},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,688331,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(688331)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(688331)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}